Loading…
Loading…
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN ® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). “Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC.
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics NASDAQ: ABEO reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company's earnings call.
Abeona Therapeutics Inc. (NASDAQ:ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter, one biopsy currently in manufacturing process, and six additional patients expected to be biopsied in the second quarter, three of whom have biopsies scheduled.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ABEO and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.